tiprankstipranks
Advertisement
Advertisement

SLXN Stock Latest News

Silexion Therapeutics Announces Immediate Board Membership Change
Company AnnouncementsSilexion Therapeutics Announces Immediate Board Membership Change
21d ago
8K
SLXN
Silexion Therapeutics approved to initiate Phase 2/3 clinical trial of SIL204
PremiumThe Fly
Silexion Therapeutics approved to initiate Phase 2/3 clinical trial of SIL204
22d ago
SLXN
Silexion gains approval for SIL204 pancreatic cancer trial
PremiumCompany Announcements
Silexion gains approval for SIL204 pancreatic cancer trial
22d ago
8K
SLXN
Silexion Shareholders Reject Capital Increase and Plan Amendments
PremiumCompany Announcements
Silexion Shareholders Reject Capital Increase and Plan Amendments
23d ago
8K
SLXN
Silexion Therapeutics urges shareholders to vote ahead of EGM
PremiumThe Fly
Silexion Therapeutics urges shareholders to vote ahead of EGM
1M ago
SLXN
Silexion Therapeutics is developing a potential “holy grail” play in precision oncology (NASDAQ: SLXN)
PremiumTipRanks NewswireSilexion Therapeutics is developing a potential “holy grail” play in precision oncology (NASDAQ: SLXN)
2M ago
SLXN
Silexion Highlights SIL204 RNAi Pancreatic Cancer Program Progress
Premium
Company Announcements
Silexion Highlights SIL204 RNAi Pancreatic Cancer Program Progress
2M ago
8K
SLXN
Silexion outlines 2026 plans after transformational 2025 progress
Premium
Company Announcements
Silexion outlines 2026 plans after transformational 2025 progress
3M ago
8K
SLXN
Silexion Therapeutics issues letter to shareholders
PremiumThe Fly
Silexion Therapeutics issues letter to shareholders
3M ago
SLXN
Silexion Therapeutics Submits Phase 2/3 Trial Application
PremiumCompany Announcements
Silexion Therapeutics Submits Phase 2/3 Trial Application
4M ago
8K
SLXN
Silexion submits Phase 2/3 trial application to Israel for SIL204
PremiumThe Fly
Silexion submits Phase 2/3 trial application to Israel for SIL204
4M ago
SLXN
Silexion Therapeutics initiated with a Buy at Litchfield Hills
PremiumThe Fly
Silexion Therapeutics initiated with a Buy at Litchfield Hills
4M ago
SLXN
Buy Recommendation for Silexion Therapeutics: Promising Developments and Market Potential in Pancreatic Cancer Treatment
PremiumRatingsBuy Recommendation for Silexion Therapeutics: Promising Developments and Market Potential in Pancreatic Cancer Treatment
4M ago
SLXN
Silexion Therapeutics Gains Positive Feedback for SIL204 Trial
Premium
Company Announcements
Silexion Therapeutics Gains Positive Feedback for SIL204 Trial
4M ago
8K
SLXN
Silexion receives positive feedback from German Health Authority for SIL204
Premium
The Fly
Silexion receives positive feedback from German Health Authority for SIL204
4M ago
SLXN
Silexion Completes Toxicology Studies for SIL204 Therapy
PremiumCompany Announcements
Silexion Completes Toxicology Studies for SIL204 Therapy
5M ago
8K
SLXN
Silexion Therapeutics completes toxicology studies for SIL204
PremiumThe Fly
Silexion Therapeutics completes toxicology studies for SIL204
5M ago
SLXN
Silexion Therapeutics reports Q3 EPS $2.88 vs $274.25 last year
PremiumThe Fly
Silexion Therapeutics reports Q3 EPS $2.88 vs $274.25 last year
5M ago
SLXN
Silexion Therapeutics files to sell 1.29M ordinary shares for holders
PremiumThe Fly
Silexion Therapeutics files to sell 1.29M ordinary shares for holders
6M ago
SLXN
Buy Rating Affirmed for Silexion Therapeutics: Promising Preclinical Data and Strategic Trial Plans Boost Investment Appeal
PremiumRatingsBuy Rating Affirmed for Silexion Therapeutics: Promising Preclinical Data and Strategic Trial Plans Boost Investment Appeal
7M ago
SLXN
Silexion Therapeutics Unveils Promising SIL204 Data
Premium
Company Announcements
Silexion Therapeutics Unveils Promising SIL204 Data
7M ago
8K
SLXN
Silexion Therapeutics announces new data in SIL204
Premium
The Fly
Silexion Therapeutics announces new data in SIL204
7M ago
SLXN

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >